Soley Therapeutics
About Soley Therapeutics
Soley Therapeutics is a science-first, tech-enabled biotechnology company that uses whole-cell sensing to translate cellular responses under stress and drug exposure into medicines. Leveraging proprietary imaging, automation, and computational analysis, they uncover how living cells decide to adapt, recover, or die to inform the discovery and development of first-in-class therapeutics. Based in South San Francisco, California, the company focuses on oncology and non-oncology complex diseases, aiming to accelerate translation from biology to clinic.
Recent News
Navigating Complexity in Emerging Biotech: Innovations, Integrations, and Initial Hurdles
Soley Therapeutics Presents Preclinical Data Demonstrating Selective Anti-Tumor Activity of STX-6398, a First-in-Class CKAP2 Modulator, at AACR 2026
The Week’s 10 Biggest Funding Rounds: XAI Leads As 2026 Is Off To A Brisk Start
Soley Therapeutics Inks $200 Million Series C
Recent Deals
No recent deals for this company.